Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A

In this video, Andreas Tiede, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the results of a trial which evaluated the safety and efficacy of emicizumab prophylaxis in patients with acquired hemophilia A (AHA). Dr Tiede also highlights the current standard of practice for patients with AHA and comments on the challenges associated with immunosuppressive therapy, which may be overcome with the use of emicizumab. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.